We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Need for Clinical Trials for Biosimilars Pits Brand Makers Against Generics
Need for Clinical Trials for Biosimilars Pits Brand Makers Against Generics
November 10, 2010
When clinical trials should be required for biosimilars is a bone of contention between brand- and generic-drug makers, with brand companies telling the FDA that regulation of biosimilars should be much tighter than that being sought by generic manufacturers.